Sala de prensa
Notas de prensa
Expertos alertan del incremento de la gota y del aumento de los pacientes hospitalizados
Un 2,4% de la población adulta española padece gota, según el estudio EPISER, lo que equivale a más de 800.000…
Menarini lanza Tenkasi, un nuevo antibiótico para las infecciones bacterianas agudas de la piel y tejidos blandos
Las infecciones bacterianas agudas de la piel y tejidos blandos (ABSSSI) constituyen una de las infecciones más frecuentes tanto en…
Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2-…
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from…
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from…
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase…
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO®(selinexor) for the Treatment of Patients with…
– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive…
